Treatment of Kaposi's sarcoma by inhibition of scatter factor

• US 5,707,624 A
• Filed: 06/03/1994
• Issued: 01/13/1998
• Est. Priority Date: 06/03/1994
• Status: Expired due to Fees

• Current Assignee: University of Michigan
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Nickoloff, Brian J., Naidu, Yahti M., Polverini, Peter J., Rosen, Eliot M.
• Primary Examiner(s): Scheiner, Toni R.
• Application Number:
  US08/253,728
• Time in Patent Office: 1,320 Days
• Field of Search: 424/145.1, 424/152.1, 424/143.1, 424/158.1, 435/7.23, 436/63, 436/64, 436/813
• US Class Current: 424/158.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Methods of treating Kaposi'"'"'s sarcoma (KS) by inhibiting the effect of scatter factor (SF), also known as hepatocyte growth factor (HGF), are provided. The methods of the present invention include antibody therapy wherein an antibody to SF is introduced into a patient to decrease active SF levels thereby decreasing the incidence of new tumors as well as leading to regression of established tumors by blocking SF-mediated tumor cell proliferation and neovascularization. The present invention further provides methods of inhibiting the effects of SF by introducing into a patient means for inhibiting binding of SF to the SF receptor, the c-met proto-oncogen. Means for inhibiting SF binding to the receptor include introducing into a patient an antibody to the c-met receptor or introducing a non-stimulatory ligand that will bind and thereby inhibit the receptor.

Claims

1. A method of inhibiting Kaposi'"'"'s sarcoma tumor cell growth in a patient comprising inhibiting the effect of scatter factor.

2. The method of claim 1, further comprising the step of administering to the patient a therapeutically effective amount of an antibody to scatter factor, in a biologically compatible form.

3. The method of claim 1, further comprising the step of blocking the c-met receptor.

4. The method of claim 2, further comprising the step of administering to the patient a therapeutically effective amount of an antibody selected from the group consisting of antibody to oncostatin M, antibody to IL-6, and combinations thereof, in a biologically compatible form.

5. The method of claim 3, wherein blocking the c-met receptor further comprises the step of administering to the patient a therapeutically effective amount of an antibody to c-met, in a biologically compatible form.

6. The method of claim 3, wherein blocking the c-met receptor further comprises the step of administering to the patient a therapeutically effective amount of a non-stimulatory ligand capable of binding but not stimulating the c-met receptor, in a biologically compatible form.

7. The method of claim 3, further comprising the step of administering to the patient a therapeutically effective amount of an antibody selected from the group consisting of antibody to oncostatin M, antibody to IL-6, and combinations thereof, in a biologically compatible form.

8. A method of treating a patient having Kaposi'"'"'s sarcoma by inhibiting Kaposi'"'"'s sarcoma tumor cell growth, comprising the step of inhibiting the effect of scatter factor.

9. The method of claim 8, wherein the step of inhibiting further comprises administering to the patient a therapeutically effective amount of an antibody to scatter factor, in a biologically compatible form.

10. The method of claim 8, wherein the step of inhibiting further comprises blocking the c-met receptor.

11. The method of claim 9, further comprising the step of administering to the patient a therapeutically effective amount of an antibody selected from the group consisting of antibody to oncostatin M, antibody to IL-6, and combinations thereof, in a biologically compatible form.

12. The method of claim 10, wherein blocking the c-met receptor further comprises the step of administering to the patient a therapeutically effective amount of an antibody to c-met, in a biologically compatible form.

13. The method of claim 10, wherein blocking the c-met receptor further comprises the step of administering to the patient a therapeutically effective amount of a non-stimulatory ligand capable of binding but not stimulating the c-met receptor, in a biologically compatible form.

14. The method of claim 10, further comprising the step of administering to the patient a therapeutically effective amount of an antibody selected from the group consisting of antibody to oncostatin M, antibody to IL-6, and combinations thereof, in a biologically compatible form.

15. A method of inhibiting Kaposi'"'"'s sarcoma tumor cell growth in a patient comprising the steps of:

a) administering to the patient a therapeutically effective amount of an antibody to scatter factor, in a biologically compatible form; and

b) administering to the patient a therapeutically effective amount of an antibody to c-met, in a biologically compatible form.

16. The method of claim 15, further comprising the step of:

c) administering to the patient a therapeutically effective amount of an antibody selected from the group consisting of antibody to oncostatin M, antibody to IL-6, and combinations thereof, in a biologically compatible form.

17. A method of inhibiting angiogenic activity in Kaposi'"'"'s sarcoma comprising inhibiting the effect of scatter factor.

18. The method of claim 17, further comprising the step of administering to the patient a therapeutically effective amount of an antibody to scatter factor, in a biologically compatible form.